Compliance and Tolerance to Oral AntiBiotherapy in Osteoarticular Infections (OTABIO)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

60 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-06-13

Study Completion Date

2026-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Bone and joint infections (BJI) are most often bacterial infections that can occur after surgery or de novo. They are rarely fatal in the short term, but are associated with significant morbidity, impaired quality of life and significant costs. Treatment of BJI is based on antibiotic therapy, often combined with surgery. Antibiotic therapy, at high doses, lasts a minimum of 6 weeks. It can be responsible for severe adverse effects. These characteristics (prolonged duration, multiple daily doses, and adverse effects) are known to negatively affect treatment adherence in general.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Adherence to Oral Antibiotics In Patients With Osteoarticular Infections

NCT03311113

Bone and Joint Infection Adherence, Medication

COMPLETED

Stool Biobanking and Impact of Antimicrobials on the Gut Microbiota in Patients With Bone and Joint Infection

NCT03633188

Infection, Bacterial

TERMINATED NA

Side Effects of Antibiotics in Bone and Joint Infections

NCT05927311

Bone Infection Joint Infection

RECRUITING

Antibiotic-related Serious Adverse Events in Obese Patients Treated for Bone and Joint Infection

NCT02861092

Obesity

COMPLETED

Biological Collection From Samples From The Gut Microbiota In Patients Having A Bone Or Joint Infection Treated By A Suppressive Subcutaneous Antibiotherapy With Betalactamine (CARBAMICROBIOTA)

NCT03550911

Bone Infection Joint Infection

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Drug-Related Side Effects and Adverse Reactions Treatment Adherence and Compliance

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Tolerance and adherence to oral antibiotics in patients managed for BJI

Patients having a BJI treated by surgery and taking at least one oral antibiotic after the surgery

Tolerance and adherence to oral antibiotics in patients managed for BJI

Intervention Type OTHER

Adherence will be measured 6 weeks (S6) and 3 months (M3) after the surgery. Tolerance will be mesured at baseline, and at 6 weeks (S6) and 3 months (M3) after the surgery.

The compliance data collected will be compared by two methods (electronic pill dispensers and questionnaire).

Patients will respond to a questionnaire about the tolerance of intraveinous antibiotics (between surgery and baseline) and oral antibiotics at baseline, and during the consultation at S6 and M3.

Responses to the compliance questionnaire will be collected during a telephone interview by a member of the Croix-Rousse pharmacy at S6 and M3. The pill organizer data from S6 and M3 will be transferred to the software by a nurse.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tolerance and adherence to oral antibiotics in patients managed for BJI

Adherence will be measured 6 weeks (S6) and 3 months (M3) after the surgery. Tolerance will be mesured at baseline, and at 6 weeks (S6) and 3 months (M3) after the surgery.

The compliance data collected will be compared by two methods (electronic pill dispensers and questionnaire).

Patients will respond to a questionnaire about the tolerance of intraveinous antibiotics (between surgery and baseline) and oral antibiotics at baseline, and during the consultation at S6 and M3.

Responses to the compliance questionnaire will be collected during a telephone interview by a member of the Croix-Rousse pharmacy at S6 and M3. The pill organizer data from S6 and M3 will be transferred to the software by a nurse.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ≥ 18 years
* Diagnosis of osteoarticular infection
* Treatment with at least one oral antibiotic for a minimum expected duration ≥ 6 weeks with an expected end of treatment date
* Patient who was informed and did not object to participate in the study

Exclusion Criteria

* Treatment for BJI with oral antibiotic without end of treatment date
* treatment for BJI with parenteral antibiotic only
* patient who doesn't have a telephone number or who doesn't want to give it
* Adults subject to a legal protection measure
* Pregnant or breastfeeding women

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No